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Abstract: Research on treatments for patients with co-occurring psychiatric and substance use disorders is of core importance and at 
the same time highly challenging as it includes patients that are normally excluded from clinical studies. Such research may require 
methodological adaptations which in turn create new challenges. However, the challenges that arise in such studies are insufficiently 
discussed in the literature. The aim of this methodology paper is, firstly, to discuss the methodological adaptations that may be required 
in such research; secondly, to describe how such adaptations created new challenges in a group-randomized clinical trial on Integrated 
Treatment amongst patients with co-occurring psychiatric and substance use disorders. We also discuss how these challenges might be 
understood and highlight lessons for future research in this field.
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Introduction
Research on treatments for patients with co-occurring 
psychiatric and substance use disorders is of core 
importance. Continuing emphasis on evidence based 
medicine calls for empirically validated treatments 
based upon rigorous treatment research methods.1,2 
The randomized controlled trial (RCT) is considered 
the best clinical research method mainly due to its abil-
ity to maximize internal validity which enables studies 
to attribute differential outcomes to the experimental 
manipulation rather than other causes.1,3 However, crit-
ical views have emerged in recent years. Whilst the tra-
ditional RCT is an excellent method in pharmaceutical 
trials on homogenous groups of patients, it is not as fea-
sible in trials with complex psychosocial interventions 
on heterogeneous groups of patients.4,5 The study of 
complex interventions in non-selected clinical popula-
tions is difficult and challenging. This is especially true 
for studies in the psychiatric and addiction field which 
include patients that are normally excluded from clini-
cal studies.6–8 Such research may require methodologi-
cal adaptations which in turn create new challenges. 
This makes a systematic use of such research meth-
odology important and evaluation reports on projects 
based on these methodologies imperative.
The aim of this methodology paper is, firstly, to 
discuss the methodological adaptations that may be 
required in clinical research on complex interven-
tions in non-selected clinical populations; secondly, 
to describe how such adaptations created new chal-
lenges in a randomized clinical trial on Integrated 
Treatment. We also discuss how these challenges 
might be understood and highlight the lessons impor-
tant for future research in this field.
clinical Research Methods  
and Adaptations
The randomized controlled trial
One main feature of the RCT is that it provides strong 
internal validity through strict inclusion and strict 
exclusion criteria. This strong internal validity, how-
ever, comes at the expense of poorer external validity 
which means reduced generalizability of the results to 
the heterogeneous groups of patients and settings in 
everyday clinical practice.6,9,10
Another prerequisite for establishing strong internal 
validity is a strict manualized treatment  conducted by 
highly trained and specialized  therapists. In  everyday 
clinical practice, however, clinicians are facing a 
wider range of disorders which requires a more eclec-
tic approach tailored to meet the differential needs of 
the individual patient. Additionally, the treatment is 
typically provided by health-care professionals with 
different experiences and training.9–11 It has often 
proved difficult to implement manualized treatment 
approaches as this presupposes basic skills, time con-
suming training and highly motivated therapists.12
Another main feature of the RCT design is that it 
intends to establish equal groups in regard to known 
and unknown confounding factors by randomization. 
However, this presupposes a sample size that is large 
enough compared to the number of variables,4 which 
might not be the case in many randomized clinical 
trials as difficulties in recruitment are more the rule 
than the exception.13–15 It is estimated that 19% of all 
worldwide pharmaceutical RCTs fail to enroll any 
patients, and that 90% fail to enroll the target number 
of patients within the target amount of time.16 There is 
no reason to believe this would be different for studies 
in the psychiatric and addiction fields as these stud-
ies include patients that are normally excluded from 
most RCTs.6–8
Another feature of rigorous RCTs is blinding 
of patients, therapists and researchers to treatment 
 allocation. However, in studies with complex inter-
ventions blinding is often difficult or even impossible 
to accomplish. This means that patients might with-
draw from the study when allocated to a less preferred 
treatment, and by this pose a threat to the between-
group equivalence.1,17 Additionally, in clinical prac-
tice the choice of treatment is usually a result of 
collaboration between the patient and the therapist.9
The pragmatic RCT
These discrepancies between the “ideal research” and 
the “real-world” settings have motivated a distinc-
tion between efficacy and effectiveness studies along 
with a search for complementary research methods. 
 Efficacy studies investigate the effect of specific 
treatment factors under ideal conditions, like strict 
RCTs with a strong emphasis on internal  validity. 
 Effectiveness studies, on the other hand, with a stron-
ger emphasis on external validity, investigate the 
effect of treatments under “real-world” conditions.18,19 
When it comes to complementary research methods, 
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these often involve modifications of the traditional 
methods. All such modifications, however, create 
new challenges.
One of these complementary research methods is 
the pragmatic RCT.9 The key aim of the pragmatic 
RCT is to reflect the heterogeneity of patients in 
clinical practice by using broader inclusion crite-
ria and keeping exclusion criteria to a minimum, 
thereby enhancing the generalizability of the RCT 
to patients and settings in everyday clinical practice. 
 Consequently, the pragmatic RCT can be regarded as 
lying in between efficacy- and effectiveness studies. 
The pragmatic RCT is also more flexible in defin-
ing the intervention and tends not to use a treat-
ment  manual. Usually the concern of the traditional 
RCT is to evaluate specific active ingredients in the 
treatments provided. The pragmatic RCT, investi-
gating more complex interventions, is more inter-
ested in examining each treatment as an entity or a 
“black box”.9 Such interventions might be impossible 
or even unethical to compare with placebo. An alter-
native would be to compare the experimental treat-
ment to “treatment as usual” (TAU). This means that 
the patients in the control group receive the treatment 
they would normally have received. However, TAU 
is a difficult term to define because it depends greatly 
on the preference, skills, knowledge and resources of 
the therapists delivering it.9
Multi-center trials
A well-known challenge in conducting trials evalu-
ating complex psychosocial interventions is that the 
expected effect-sizes tend to be small, especially 
when the control condition is TAU or another active 
treatment which will also constitute a treatment effect. 
Frequently, such studies require large sample sizes 
to ensure sufficient statistical power.  Additionally, 
inclusion, treatment adherence and follow-up is often 
challenging when studying patients with multiple 
 disorders. This renders studies vulnerable to type 
2 statistical error. One way of meeting this challenge 
is to use a multi-center design. If no single center has 
a sufficient case load, trials including patients from 
several centers might provide an adequate study pop-
ulation. In multi-center studies, the randomization of 
participants might be done on an individual or center-
level, ie, the individually randomized group treat-
ment trial (IRGT) or the group-randomized  clinical 
trial (GRCT).20 Individual randomization is  usually 
applied when the intention is to study effects at the 
individual level. The group-randomized clinical trial 
is useful in examining the context in which the ther-
apy is given or the differences of interventions in spe-
cific groups (schools, hospitals, etc.).20  Additionally, 
GRCTs may reduce the risk of contamination between 
treatment conditions. In treatment research on psy-
chosocial methods it is difficult to hide or mask the 
different methods that are to be randomized. This cre-
ates a risk of contamination of knowledge between the 
therapists and patients in the intervention and control 
groups. In the GRCT the different centers are allo-
cated to the different treatment conditions as a whole. 
All the therapists in one center will therefore belong 
to the same treatment condition, minimizing the risk 
of contamination.21
However, multi-center trials represent organiza-
tional, administrative, economic, treatment fidelity 
and statistical challenges. In order to secure inclu-
sion, fidelity, protocol adherence and data quality, it 
is essential to have a trial administrator at each center 
managing and monitoring the trial.1,22 Additionally, 
one has to consider clustering of participants in both 
types of multi-center trials. In the IRGT clustering 
may develop during the course of the trial, whilst 
one has to consider clustering from the start of the 
trial in the GRCT. This clustering threatens the sta-
tistical assumption of independent observations and 
should be accounted for by hierarchical statistical 
analyses.20,23–25 Further, such intra-class correlations 
may reduce statistical power and should be compen-
sated for in protocol sample size calculations.26–28
Methodological choices Made  
in a Trial on Integrated Treatment
This study was designed to investigate the effective-
ness of Integrated Treatment (IT) amongst patients 
with anxiety and/or depression in addition to sub-
stance use disorders (SUD) in psychiatric outpa-
tient clinics of Community Mental Health Centers 
(CMHCs) in Norway. The control condition was 
treatment as usual (TAU). IT is a combined treat-
ment for both the psychiatric and the substance use 
problems of the patient. The main components of IT 
are Motivational Interviewing and Cognitive Behav-
ioral Therapy along with a more active and com-
prehensive treatment approach.29 The treatment was 
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not  manualized, but a descriptive clinical guideline 
 manual was provided and used in staff training. Three 
to five therapists at each clinic in the Intervention 
Group received training in IT. The clinicians in the 
control group were promised teaching of the experi-
mental intervention when the study was over.
To obtain external validity, we chose a prag-
matic RCT design. In order to acquire the calculated 
 sample-size, we chose to run a multi-center study. 
As contamination of knowledge between therapists 
and patients between groups was an obvious risk, we 
decided to randomize on center-level. Blinding was 
judged impossible and therefore the allocation was 
open at inclusion. In order to secure inclusion, treat-
ment fidelity, protocol adherence, and data quality, 
we chose to train and pay one therapist at each center 
in a 10% position as a local trial administrator.
The CMHCs were randomized by draw at the center-
level. The groups were stratified with respect to urban 
or rural catchment areas. Five centers were drawn to the 
intervention group and four centers to the control group.
All new referrals to the psychiatric outpatient clin-
ics during the inclusion period were to be screened 
with the Alcohol Use Disorder Identification Test 
(AUDIT)30 and the Drug Use Disorder Identification 
Test (DUDIT).31 Those who scored above the cut-off 
levels associated with abuse or dependence were sub-
sequently referred to the local trial administrator for 
assessment of the inclusion criteria. The diagnostic 
inclusion criteria were assessed with the Structured 
Clinical Interview for the DSM-IV diagnoses, ie, the 
SCID 132 and the SCID 2.33
The local trial administrators had 3 days of training 
in how to run the project and in using the evaluation 
instruments including the SCID and the Addiction 
Severity Index (EuropASI), chapter E.34,35 The train-
ing on the research instruments consisted of lectures, 
clinical examples and practicing on case vignettes.
The included patients were assessed at base-
line, 6 and 12 months. According to the local trial 
administrators, the baseline interviews took between 
2–5 hours, and the follow-up interviews took between 
1–3 hours each.
According to power calculations 108 patients 
were needed. As we expected between 20 and 30 per-
cent to drop out from treatment and assessments, we 
aimed to include a total of 150 patients in the study 
(ie, N = 75 in each group). Thus, each of the 9 CMHCs 
were expected to include between 15 and 20 patients. 
The study was approved by the Norwegian Regional 
Ethics Committee.
challenges experienced
Center recruitment
Considerable time was spent on recruiting CMHCs into 
the trial. Thirty five CMHCs from 3 out of 5 Regional 
Health Trusts were invited. More information was pro-
vided through meetings at the CMHCs that responded 
positively to the invitation. Most of the CMHCs were 
positive with respect to gaining knowledge about the 
effects of the intervention, but reluctant in regard to 
the workload demanded by such studies. In the end, 10 
CMHCs agreed to participate in the study. However, 
one center withdrew just before randomization, leav-
ing us with a total of 9 centers. The recruitment process 
significantly delayed the initiation of the project and 
put the trial behind schedule from the beginning.
The contracts between the participating CMHCs 
and the project management would have to be worded 
differently between the experimental and the con-
trol group. We therefore decided to make the written 
agreements with each participating center after treat-
ment allocation. This turned out to be a mistake as 
one of the centers allocated to the control group with-
drew 2 months into the project. They stated this was 
due to workload and staffing problems. During the 
course of the trial, another center in the control group 
did not manage to include any patients. As failing to 
include the target number of patients would mean 
risking type two statistical error, several attempts 
were made to include additional centers to the control 
group even though it would have compromised the 
RCT design. Towards the end of the study period, we 
managed to include two more centers which, how-
ever, did not manage to include any patients. This left 
us with 5 centers in the Intervention Group (IG) and 
two centers in the Control Group (CG) (Fig. 1).
Patient recruitment
A total of 5323 patients were referred to the CMHCs 
during the inclusion period (Fig. 2). Only 35% of 
these patients were actually screened with the AUDIT 
and the DUDIT (CG: 50%, IG: 27%) with a range 
from 17%–64% between CMHCs (data not shown). 
Of these 1867 patients, 88 (5%) handed in a blank 
form (CG: 7%, IG: 3%). All of the blank forms from 
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the CG came from the CMHC that did not manage 
to include any patients and constitutes 20% of the 
screened forms from that CMHC.
Eighteen per cent of the screened patients scored 
above the cut-off level of the AUDIT and/or the 
DUDIT (CG: 10%, IG: 27%), ranging from 5%–34% 
between centers. Only 31% of those that scored 
above the cut-off level were actually referred to the 
local trial administrator for the baseline evaluation 
(CG: 33%, IG: 30%), ranging from 0%–50% between 
centers. The main reason for not being referred was 
“no oral consent to participate in the study” (CG: 32%, 
IG: 59%). Another reason was that the clinicians 
deemed the patient’s motivation for substance use 
treatment as being too low (IG: 0.04%) or that the 
patient was not in need of such treatment (CG: 14%). 
The latter reason was only stated by the CMHC that 
did not manage to include any patients.
In the end, only 81 patients were included in the 
study. This was 4% of the total number of screened 
patients and 24% of the patients that scored above the 
cut-off level of the AUDIT and/or the DUDIT (CG: 
2%, 25%, IG: 6%, 23%), ranging from 0%–7% and 
15%–40% respectively, between centers. After inclu-
sion, 2 patients in the CG and 3 patients in the IG 
withdrew their consent, leaving us with 21 patients 
in the CG and 55 patients in the IG. This means that 
the number of participants available for the intention 
to treat analyses were 76, ranging from 6–16 partici-
pants between centers.
After inclusion, two patients in the IG never met for 
treatment, 11 patients received less than 5  sessions (CG: 
3, IG: 8) and 14 patients never returned for  follow-up 
interviews (CG: 3, IG: 11) (Data not shown). This left 
us with 56 completers, defined as receiving 5 sessions 
or more and meeting for at least one follow-up inter-
view (CG: 17, IG: 39), ranging from 4–14 between 
centers. Only 48 patients had at least 5 sessions and 
met for both follow-up interviews (CG: 15, IG: 33) 
(data not shown). There was no significant difference 
in the number of completers between the IG and the 
CG (χ2 = 0, 80; df = 1; P = 0, 374).
There were three main differences in the referral 
policy of patients with SUD across centers. At one 
extreme, the centers referred all patients with SUD to 
the addiction outpatient unit except patients with co-
occurring schizophrenic spectrum disorders. Other 
CMHCs treated patients with co-occurring SUD at the 
psychiatric outpatient clinic as long as the SUD was 
not severe (harmful use and abuse only). At the other 
extreme, one CMHC treated all patients with men-
tal illness at the psychiatric outpatient clinic regard-
less of co-morbid SUD. We found that the CMHC 
that failed to include any patients was amongst the 
four CMHCs that referred all patients with co-morbid 
SUD to the addiction outpatient unit. The one CMHC 
that did not refer patients with SUD elsewhere was 
the only CMHC that managed to include the target 
number of patients during the initial inclusion period. 
Otherwise, we did not find any relationship between 
the center referral policy and the number of people 
that scored above the threshold level of the screening 
instruments (data not shown).
The inclusion period proved to be insufficient. 
After the planned inclusion period of 9 months only 
one CMHC had managed to recruit the target num-
ber of patients and only 55 patients were included in 
total (CG: 14, IG: 41). The remaining CMHCs and 
their coordinators were willing to continue  recruiting 
Stratified randomization
9 CMHCs
included in the study  
Intervention group:
5 CMHCs  
Control group:
4 CMHCs 
1 CMHC withdrew
after 2 months.
No patients included 
Control group:
2 CMHCs (N = 23)  
1 CMHC   (N = 0)
Intervention group: 
5 CMHCs (N = 58)
2 additional CMHCs
were recruited but  
failed to include 
patients 
10 CMHCs
accepted to participate   
1 CMHC
withdrew before  
randomization 
35 CMHCs
were asked to participate  
25 CMHCs
did not want to  
participate
CMHC 1:   6 patients 
CMHC 2: 14 patients 
CMHC 5: 16 patients 
CMHC 7:   8 patients
CMHC 9: 14 patients
CMHC 4: 15 patients 
CMHC 6:   8 patients 
CMHC 8:   0 patients 
Figure 1. Flowchart of CMhCs on centre level.
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for another 3 months. Nevertheless, after those 
3 months only 74 patients were included (CG: 18, 
IG: 56) (data not shown). The remaining CMHCs 
were asked to continue recruiting until the target 
number of patients was included or until the end of 
the year (another 9 months). All CMHCs from the 
CG and one CMHC from the IG accepted this. Still, 
patient enrolment was slow and one CMHC (CG) 
did not manage to recruit any patients at all by the 
end of the additional year.
Intervention group Control group
New referrals meeting for 
first session:
5325
IG: 3421
CG: 1904
New referrals, screened 
with AUDIT and DUDIT:
1867
IG: 923
CG: 944
Under cut-off: 628
Blanc form: 25
Acute illness: 7
Clinician deemed patient
”ineligible”: 7
Other:   9*
*Foreign language, referred for assessment
only     
Screened patients scored 
above cut-off level: 
340
IG: 247
CG: 93
No oral consent: 145
Acute illness/too ill: 10
Referred to addiction treatm.: 2
Clinician deemed patient not 
eligible: 4
Unknown: 7
Other: 5**
**Planning to move, referred for assessment  
only
Patients above cut-off, 
referred for baseline 
evaluation:
105
IG: 74
CG: 31
Not met for/not completed 
evaluation: 8
Exclusion criteria met: 5 
Inclusion criteria not met: 2
Withdrew consent: 1
Included in the study:  
81
IG: 58
CG: 23
Withdrew consent: 3
Never met for follow-up
interviews or met for less than 5 
treatment sessions: 16  
Intention to treat N = 55 
Completers N = 39 
Under cut-off: 788 
Blanc form: 63  
Acute illness: 0 
No oral consent: 30
Referred to addiction treatm.: 5  
Referred to other treatment: 2  
Treatment started before 
baseline evaluation: 8 
Clinician deemed patient not 
eligible: 13
Other: 4***
***Foreign language, planning to move,  
referred for assessment only  
Not completed evaluation: 6 
Exclusion criteria met: 1   
Inclusion criteria not met: 1 
Withdrew consent: 2
Never met for follow-up 
interviews or met for less than 5 
treatment sessions: 4
Intention to treat N = 21
Completers N = 17 
Figure 2. Flowchart of patients in the intervention group and the control group.
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In the CMHC that managed to include the  target 
number of patients during the initial recruiting 
period, another problem arose. They had so many eli-
gible patients that it exceeded the treatment capacity 
of the clinicians that were trained in the experimen-
tal intervention. They therefore stopped recruiting 
when the minimum number of required patients was 
included, 2 months ahead of schedule. To address 
this problem we chose to train two additional thera-
pists at that clinic.
Follow-up interviews
The next challenge was to get patients to return for 
the follow-up assessments. One CMHC (IG) man-
aged to complete follow-up interviews for all patients 
at 6 and 12 months. At the other extreme, one CMHC 
(IG) lost 6 out of 14 patients at both follow-up  sessions. 
The other CMHCs lost 1–2 patients each from both 
follow-up sessions (data not shown). In order to 
reduce drop-out from the follow-up assessments, the 
patients were offered €25 for each follow-up session 
as a compensation to cover their travel expenses. The 
Regional Medical Ethics Committee did not accept a 
higher monetary incentive, to prevent it from becom-
ing an incentive for participation on its own.
Discussion
This study illustrates the difficulties experienced 
in a multi-site group-randomized clinical trial with 
complex interventions in a non-selected clinical 
 population. In our study the problems arose early 
while recruiting centers. Further problems arose while 
recruiting patients and encouraging them to return for 
their follow-up assessments.
Recruiting centers
The first time-consuming challenge was recruiting 
centers. Thirty five CMHCs were asked to participate 
and only 9 accepted. The main reasons for declin-
ing participation were challenges in the clinics with 
respect to time and financial demands. Other reasons 
were shortage of specialists, lack of a local support-
ive infrastructure, inadequate research training, and 
data collection challenges. It seems that many clinics 
value research and want to contribute to it, but few 
have the resources needed to follow it through. This 
was clearly demonstrated when one of the participat-
ing CMHCs withdrew 2 months into the project.
Researchers have a formidable challenge in both 
motivating centers to contribute to research and to keep 
the burden of participation at an acceptable level. If the 
burden of participation is too high, the study will run 
the risk of collecting incomplete and missing data. To 
accomplish good motivation, adherence and implemen-
tation of research methods in the clinic, it is important 
to involve the clinics in the project at an early stage and 
to let them contribute actively in the planning and exe-
cution phases of the project.36,37 This will both enhance 
the centers’ feeling of “ownership” towards the study, 
and also contribute to a design that is in accordance 
with the clinics’ needs and workload. However, mak-
ing contracts with the clinics at an early stage might be 
premature due to high application refusal rates.
Some of the clinic leaders stated that they would 
not want to participate in the study if they were allo-
cated to the control group, as it would not be worth the 
effort for them. This highlights further the importance 
of including the centers at an early stage of the study 
planning process and to use strong acknowledgement 
and reinforcement strategies. Strong reinforcements 
are essential to make the effort of participation worth-
while regardless of allocation. One reinforcement 
strategy could be to give the co-workers at the cen-
ters a role that fulfills the Vancouver requirements for 
 co-authorship.36 In our study the control group centers 
were promised ownership of all data from their own 
center along with treatment manuals and teaching in 
the experimental intervention after the study.
The local trial administrators have an important 
role in the study and it is essential to select appropri-
ate people for these positions. However, we did not 
have the luxury of selecting between several candi-
dates for the job. At most CMHCs it was difficult to 
find even one single interested person. Thus, the local 
trial administrators were a mix of people with vary-
ing education, training, interests, motivation and time 
available for the trial. Furthermore, the more centers 
that are involved in a multi-site trial and the larger the 
geographical area they are spread over, the greater the 
responsibility and project work-load for the local trial 
administrators. This could create differences in how 
the data is collected between centers.
Recruiting patients
The therapists at the CMHCs were supposed to screen 
all new referrals with the AUDIT and the DUDIT. 
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However, only 35% were actually screened. 
 According to the local trial administrators this was 
due to several factors. Some therapists felt the screen-
ing was a new burden on their already busy sched-
ule, some felt insecure addressing the issue of alcohol 
and drug use and that it was particularly awkward 
to introduce this subject during the first session and 
some were concerned it would threaten the therapeu-
tic alliance to address such a delicate issue. In one 
center the leader had resigned shortly after the project 
started. His successor had little interest in the project 
and did not encourage or support the staff to continue 
screening. Most local trial administrators, however, 
commented that they found the screening relevant 
and some of the clinics even wanted to keep it as part 
of their routine after the project was over.
Our understanding is that these problems were insuf-
ficiently considered. Therapists are often uncomfort-
able with addressing the issue of alcohol and drug use 
with the patient and need extra coaching.38–42 Unless 
the importance of screening is strongly emphasized 
by the local trial administrator and/or the research 
group and followed by strong support from the clinic 
management, such new routines are easily  forgotten. 
Most clinical research projects require the establish-
ment of new routines to gather the required data for 
the project. Implementation of new routines and 
treatment methods has long shown to be a challenge 
in most settings and require formidable resources on 
many levels.43,44 Ideally, such routines should be well 
established before the start of the study.36
An unforeseen problem was the very low preva-
lence of patients with problematic alcohol and drug 
use identified by the AUDIT and the DUDIT in some 
of the CMHCs. From previous prevalence findings 
of SUD in psychiatric outpatient clinics, one would 
expect this number to be higher.45,46 This might be 
explained by different referral policies between 
 centers. During the planning phase of the project 
new national mental health services guidelines were 
published. These guidelines were interpreted differ-
ently by the centers. One interpretation was to estab-
lish separate addiction outpatient units as part of the 
CMHC, rendering the psychiatric outpatient clinic of 
the CMHC almost deplete of patients comorbid of 
mental and SUD.
The therapists were asked to refer all patients that 
scored above the cut-off level of the AUDIT and the 
DUDIT to the local trial administrator for baseline 
evaluations. However, only about a third were actu-
ally referred. The main reason for this was that the 
patients did not want to participate in the study. In the 
Intervention Group, participation in the study could 
imply a change of therapist to one that had learned the 
intervention. This, however, does not explain why the 
patients in the Control Group refused to participate. 
This could be due to how the therapists presented the 
project to the patients, perhaps reflecting their own 
attitudes towards the project.44,47 At one CMHC the 
clinicians deemed 13 patients as not needing treat-
ment although they scored above the threshold level 
of the screening instruments. Considering this was the 
CMHC that did not manage to include any patients, 
this could mean that the project was not well enough 
implemented in that clinic. Several studies have 
stated that a prerequisite for implementing a trial into 
a clinical setting is a supportive clinic management 
that motivates the clinicians to participate.43,44
We soon realized that inclusion was happening too 
slowly, so we contacted the CMHCs and urged their 
management to make sure that the psychiatric outpa-
tient clinics would take responsibility for their share 
of patients with co-occurring SUD instead of refer-
ring them elsewhere. This created several dilemmas. 
In the Control Group it would be unethical to keep 
the patients with co-occurring SUD at the psychiat-
ric outpatient clinics if they did not feel they had the 
competency to treat them there. On the other hand, 
different policies in handling referrals in regard to 
co-occurring SUD between the IG and the CG would 
bias our sample. Additionally, our Intention to Treat 
(ITT) design would keep the patient data in the group 
they were allocated to even though the patients were 
referred to another treatment facility (eg, addiction 
treatment) after inclusion in the study. This means 
that if the CG would refer their patients to an addic-
tion treatment facility, it would make it difficult to 
conclude whether there were any real differences in 
the interventions given between the IG and the CG.
To address the slow inclusion rate, we extended the 
inclusion period by one year. Extending the inclusion 
period is problematic in several ways. It exceeds the 
original funding and increases the risk of having to 
deal with therapist turn-over.48,49 During the first year 
of the project, we had to train 4 additional therapists. 
We experienced that the extended inclusion period 
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did not increase inclusion numbers to a great extent. 
During the initial inclusion period we included about 
37% of the calculated sample size needed. After the 
first 3 months of the extended inclusion period we 
had included 49% of the calculated sample size, and 
we ended up with only 51% (ITT) of the calculated 
sample size after an additional year of recruiting. This 
means that the cost of extending the inclusion period 
is greater than the benefit.
Follow-up assessments
Not unexpectedly, follow-up proved challenging. As 
the first CMHC to finish including patients experi-
enced great difficulties in reaching the patients for 
follow-up assessments, we applied for additional 
funding to pay the participants a symbolic amount 
for their participation in the study. This necessi-
tated additional approval from the Regional Medical 
 Ethics Committee. We are unsure if this payment had 
an effect on follow-up rates. The additional strate-
gies employed seem more important. Many of the 
local trial administrators used a lot of creativity in 
reaching the patients for their follow-up assessments, 
such as interviewing patients that had moved to other 
parts of the country by phone and mail and making 
appointments for interviews at the patient’s work-
place when the patient was unable to visit the clinic. 
Our experience is that the local trial administrators 
who put more effort into the task than was expected 
of them and who where the most creative, man-
aged to reach the most patients for their follow-up 
 assessments. Our interpretation is that this type of 
research puts heavy demands on the participating 
centers and local trial administrators, and that these 
demands and costs are often underestimated. The 
result might be under-funding and the use of inad-
equate strategies which could easily endanger multi-
site studies. Securing adherence is a complex issue 
that requires multiple and comprehensive strategies 
at different stages of the trial.50,51 This requires the 
researchers to be directly involved and integrated into 
the research work of each center, thereby improving 
data quality and adherence.43,44
ethical considerations
Commonly, clinical trials encounter problems in 
recruitment, follow-up and adherence which may 
reduce the studies’ probability of demonstrating an 
effect (type 2 statistical error). This is ethically prob-
lematic because one risks wasting financial and human 
resources. The Medical Ethics Committees therefore 
make an assessment of the realism in each project 
prior to approval. When encountering such challenges 
during the course of the trial the researchers are faced 
with the choice of aborting the study or reinforcing 
the measures. To be able to make these choices at the 
appropriate time the researchers need to monitor 
the project continuously and to have created strate-
gies on how to handle such difficulties in advance. 
In our case, we chose to reinforce the measures by 
training additional therapists, extending the inclusion 
period and providing monetary incentives. The latter 
two reinforcement strategies necessitated additional 
approval from the Regional Ethics  Committee. In 
either case, whether the researchers choose to abort 
the study or to reinforce the measures, the researchers 
have an ethical obligation to report these challenges 
in a way that prevents other researchers from encoun-
tering the same problems.
Lessons Learned
This study illustrates common challenges in conduct-
ing pragmatic multi-site group-randomized studies on 
heterogeneous groups of patients with multiple prob-
lems and complex intervention methods. The study 
shows that although it is difficult and challenging, it 
is possible to conduct such a study. In communicat-
ing with clinicians and patients, the study has been 
regarded as interesting and worthwhile. This points 
towards possibilities and potentials.
The first challenge we met was difficulties in 
recruiting centers and motivating their participation 
regardless of which treatment condition they would 
be allocated to. The lesson is to involve the participat-
ing centers at an early stage of the planning phase of 
the study. This will both enhance the centers’ feeling 
of “ownership” towards the study, and also contrib-
ute to a design that is in accordance with the clinics’ 
needs and workload.
Our second challenge was that the local trial 
administrators were a mix of people with different 
education, training, interests, motivation and time 
available for the trial. The lesson is to visit each 
center regularly, at least once a month, to ensure 
data-quality at each center and uniformity in data 
collection between centers.
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Our third challenge was that the therapists did not 
comply with the screening routines of the study. This 
might be explained by heavy work-load, difficulties 
in thematizing substance misuse and lack of sup-
port from the clinics’ management. The lesson is to 
make sure that the new routines are well implemented 
before the start of the trial.
Our fourth challenge was different referral policies 
between centers and that these policies were changed 
during the planning phase of the trial due to new national 
guidelines. This affected the number of patients eligible 
for the trial. The lesson is to be aware of policies (for-
mal and informal) and organizational changes and to 
take them into consideration when planning the study.
Our fifth challenge was that a low percentage of the 
patients that screened positive for substance use disorders 
were referred for the inclusion assessments of the trial. 
The main reason was lack of consent from the patients. 
This might be explained by how the study was presented 
to the patients by the therapists. Again, the lesson is to 
involve the centers at an early stage of the planning phase 
of the project, ensuring a feeling of “ownership” towards 
the study, and to make sure that the center management 
is supportive and encouraging towards the therapists in 
complying with the demands of the study.
Our sixth challenge was the slow and, ultimately, 
low inclusion rate. Our experience is that extending the 
inclusion period did not increase the inclusion num-
ber to a great extent. The lesson is to focus all efforts 
and resources on the original recruitment period. This 
is when all the participants of the study are still fully 
focused on this one task, and one minimizes the risk of 
therapist turn-over and other additional costs.
Our seventh and last challenge was to encourage 
patients to return for the follow-up assessments. Our 
experience is that the local trial administrators who put 
more effort into the task than was expected of them and 
who where the most creative, managed to reach the most 
patients for their follow-up assessments. The lesson is 
that this type of research puts heavy demands on the 
participating centers and local trial administrators, and 
that these demands and costs are often underestimated.
Summing up
Studies of complex interventions in unselected clinical 
populations are essential in the development of evidence 
based treatments in the psychiatric and addiction field. 
The methodological problems are considerable but it is 
possible to overcome the challenges by thorough plan-
ning and addressing the obstacles at an early stage.
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